In This Article:
H.C. Wainwright analyst Joseph Pantginis raised the firm’s price target on Aptose Biosciences (APTO) to $6 from $2 and keeps a Buy rating on the shares. The firm is adjusting its estimate of the fully diluted share count based on the February 1:30 reverse split, removing second-line use of tuspetinib for acute myeloid leukemia from projections since the primary focus is on the triple first-line path and adjusting its projected launch year for first-line AML to 2030 in the U.S.
Don't Miss Our End of Quarter Offers:
-
Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks.
-
Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on APTO: